The antibody drug conjugate (trastuzumab emtansine) showed promising tumor inhibitory effect in preclinical studies, but in one randomized trial, T-DM1 was not superior to chemotherapy in patients with HER2-positive advanced gastric cancer [7]. The gene discussed is ERBB2; the disease is neoplasm.